Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92369 | 0.90 | RAB9A (0.64) | RAB9APOLBTDP1GAANPC1 | |
| SCHEMBL10273139 | 0.90 | RAB9A (0.59) | RAB9APOLBTDP1GAANPC1 | |
| SCHEMBL93044 | 0.89 | RAB9A (0.46) | RAB9APOLBTDP1GAANPC1 | |
| SCHEMBL93047 | 0.86 | RAB9A (0.43) | RAB9APOLBTDP1GAANPC1 | |
| SCHEMBL92613 | 0.84 | RAB9A (0.56) | RAB9AGAANPC1SMN1; SMN2MAPT | |
| SCHEMBL10273155 | 0.83 | MAOB (0.47) | RAB9APOLBNPC1SMN1; SMN2MAOB | |
| SCHEMBL92605 | 0.82 | MEN1 (0.57) | RAB9APOLBGAANPC1SMN1; SMN2 | |
| SCHEMBL19657565 | 0.79 | NR4A2 (0.68) | POLBMAOBNR4A2L3MBTL1 | |
| SCHEMBL10285849 | 0.79 | RAB9A (0.46) | RAB9APOLBTDP1GAANPC1 | |
| SCHEMBL10273947 | 0.79 | NR4A2 (0.43) | RAB9APOLBNPC1SMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | RAB9A 1187/4885POLB 3232/4885TDP1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.